Bank of Montreal Can Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of Montreal Can lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 30.6% in the third quarter, HoldingsChannel reports. The firm owned 2,086,322 shares of the biotechnology company’s stock after purchasing an additional 489,320 shares during the quarter. Bank of Montreal Can’s holdings in ADMA Biologics were worth $40,443,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. D. E. Shaw & Co. Inc. boosted its stake in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after purchasing an additional 447,743 shares in the last quarter. Renaissance Technologies LLC raised its holdings in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after purchasing an additional 575,100 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in ADMA Biologics by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock worth $48,007,000 after purchasing an additional 249,412 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Trading Up 0.0 %

Shares of ADMA stock opened at $21.83 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a market cap of $5.16 billion, a price-to-earnings ratio of 77.96 and a beta of 0.64. The stock has a 50 day simple moving average of $19.08 and a 200-day simple moving average of $15.23. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period in the prior year, the company posted $0.01 EPS. On average, equities research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.